



May 10, 2023

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE Prime Market)
Contact person: Kenji Yamada, Senior Vice President,
Corporate Administration Headquarters
(TEL. +81-3-6711-5200)

Japan Lifeline Launches Wallaby Medical's Esperance Aspiration Catheter

Japan Lifeline Co., Ltd. ("Japan Lifeline") is pleased to announce that it began marketing the Esperance aspiration catheter ("Esperance"), a thrombus aspiration catheter manufactured by Wallaby Medical, LLC. ("Wallaby Medical") in May 2023.

Doctors treat acute ischemic stroke by dissolving the blood clot in the brain's blood vessels with medicine or removing it with a special catheter called thrombus aspiration catheters. Due to updated treatment guidelines in 2019, more patients can now benefit from endovascular treatment, and thus the market for this treatment is expected to grow.

The Esperance has a thin tube with a large lumen and small outer diameter, allowing it to make better contact with clots for easier removal of large clots and better blood flow. Its design makes it easy for surgeons to move the device to the clot even in twisted blood vessels. These qualities help improve endovascular treatment results.

Japan Lifeline is focusing on neurovascular diseases and has an exclusive 10-year distribution agreement with Wallaby Medical in Japan for their endovascular treatment devices. In addition to the Esperance, Japan Lifeline plans to release a microcatheter for treating acute ischemic stroke during the FYE March 2024. The company is already selling embolic coils for treating cerebral aneurysms, which have been approved by the medical community. Japan Lifeline is eager to expand its product lineup to meet the different needs of endovascular treatment for neurovascular diseases.



The Esperance Aspiration Catheter